<DOC>
	<DOCNO>NCT01114165</DOCNO>
	<brief_summary>The overall objective study assess clinical value SeptiFast Test adjunct traditional microbiological , clinical , laboratory assessment early detection identification potential pathogen therefore early target antimicrobial management neutropenic hematological patient suspect infection sepsis .</brief_summary>
	<brief_title>Value LightCycler® SeptiFast Test MGRADE Pathogen Detection Neutropenic Hematological Patients</brief_title>
	<detailed_description>Infections , include sepsis , continue major cause morbidity mortality patient hematologic disease . Early diagnosis infection , rapid identification causative pathogen ( ) , prompt initiation appropriate antimicrobial treatment ( first 24 hour critical ) major impact mortality . The LightCycler® SeptiFast Test MGRADE ( SeptiFast Test ) vitro nucleic acid amplification test direct detection identification DNA bacterial fungal microorganism human EDTA whole blood . The SeptiFast test detect nucleic acid common pathogen ( approximately 90 % ) responsible hospital-associated bacteremia . The test use conjunction patient 's clinical presentation establish microbiological assay laboratory marker aid antimicrobial treatment decision make patient suspected sepsis bloodstream infection . This randomized prospective study use SeptiFast Test adjunct traditional management neutropenic haematological patient suspect infection sepsis . The study perform two-armed manner . The blood sample SeptiFast Test collect include patient . However , analysis SeptiFast Test control group perform later point time ; thus , control group result become available end study , therefore , use guide clinical decision . Patients complete study episode infection sepsis resolve , patient discharge hospital , patient die .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>1 . Patient hematological disease neutropenia &lt; 500/µl ( &lt; 1000/µl , criterion 5A fulfil ) 2 . Known acute infection , suspect infection , sepsis , clinically indicate investigation blood culture 3 . Timeframe diagnosis suspicion infection sepsis : &lt; 72 hour 4 . Species cause infection know inclusion 5 . Patient fulfil criterion A or/and B A . Indication initiation antimicrobial therapy patient febrile neutropenia Neutropenia &lt; 500/µl &lt; 1000/µl decline &lt; 500/µl expect next 48h . Single ( oral ) temperature ≥ 38.3°C , temperature ≥ 38.0°C last least 1h measured twice within 12h . No evidence noninfectious cause fever ( blood product , drug reaction , etc ) B . At least two follow criterion : Temperature &gt; 38°C &lt; 36°C Heart rate &gt; 90 beats/minute Respiratory rate &gt; 20 breaths/minute PaCO2 &lt; 32 mmHg / 4,3 kPa 6 . Patient able provide write informed consent 1 . Moribund patient survival expectation &lt; 24h 2 . Younger 18 year 3 . Patient able provide inform consent 4 . Patients suitable study participation opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Febrile Neutropenia</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Polymerase Chain Reaction</keyword>
</DOC>